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One of the first hallmarks noted by the
CDC at the beginning of what became
the AIDS epidemic in the United States
was the sudden unusual occurrence of
cancerous red skin lesions in a cohort of
young homosexual men in New York and
San Francisco.These angiogenic lesions
known as Kaposi’s sarcoma (KS) resem-
bled those in rare cases (defined origi-
nally in 1870) in elderly Mediterranean
Jewish men and also those in a later,
more aggressive version in Central
Africa (starting in the 1950s). We now
appreciate that all forms of KS (epidem-
ic, classic, introgenic, and endemic) are
associated with infections by a novel
herpesvirus known as KSHV or HHV8
discovered in KS lesion tissue in 1994
(Chang et al., 1994). This is normally an
extremely rare disease correlating with
low seropositivity rates in most parts of
the world, except sub-Saharan Africa
(60%) and the Mediterranean (5% to
20%). However, the rates of KS disease
increase up to 500-fold in solid organ
transplant patients and up to 20,000-fold
in male homosexual AIDS patients. The
huge increase in KS in Southern Africa,
where it is now the most frequently
encountered cancer, represents a com-
bination of the introduction of novel HIV
infection-related immunosuppression
with a population that was already
almost ubiquitously but asymptomatical-
ly infected by KSHV. Nevertheless, it is
very evident that HIV alone does not
cause KS, whereas KSHV is essential
for KS lesions to form (Jenner and
Boshoff, 2002).
There is no clear explanation of why
HIV infection specifically depresses nor-
mal cell-mediated immunological control
of KSHV, which is presumed to be dor-
mant in latently infected B cells and per-
haps other myeloid or endothelial cells
(EC); however, dysregulation of immune
cytokine and chemokines and perhaps
the Tat protein is presumed to lead to
reactivation and spread of KSHV to der-
mal vascular or lymphatic endothelial
cells, which then convert into the charac-
teristic spindle cell phenotype and
proliferate as an unusual viral-driven
neoplasia with angiogenic characteris-
tics. In late stage nodular or disseminat-
ed KS, essentially all spindle cells are
latently infected by KSHV and express
just the viral LANA-1 protein and proba-
bly also the vCyc-D and vFLIP proteins
(Dupin et al., 1999; Jenner and Boshoff,
2002). LANA-1 is a chromatin-interacting
repressor that binds to the multicopy epi-
somal viral genomes giving a distinctive
punctate nuclear pattern. It probably
plays a role in both segregation of
progeny genomes and cell growth con-
trol. Both LANA-1 and vCyc-D have pro-
mitotic properties, and vFLIP has
anti-apoptotic activity as well as upregu-
lating NFKB, a key feature of several rare
KSHV-associated lymphomas such as
primary effusion lymphoma (PEL) and
multicentric Castleman’s disease (MCD)
that also occur at increased frequency in
AIDS patients. Infectious KSHV virions
derived from TPA-treated PEL cell lines
can be used to infect cultured normal pri-
mary human dermal microvascular
endothelial cells (DMVEC) to produce
LANA-1-positive latently infected cells
with a proliferating spindle cell pheno-
type that closely resembles KS (Ciufo et
al., 2001).
Unlike HIV, KSHV is clearly an
ancient human virus that has coevolved
with its migrating human host since at
least the origin of modern humans in
Africa, and almost certainly throughout
mammalian evolution, judged by the
presence of closely related viruses in
chimpanzees and in a number of other
old world primate species. However,
unlike with other more typical and ubiqui-
tous human herpesviruses, KSHV infec-
tion (presumed to be through saliva) is
apparently relatively inefficient and may
not have had time to catch up with the
relatively recent rapid expansion of
human populations (outside of Africa)
after migration to new continents or from
the Ice Age refuges in Europe and Asia
(Zong et al., 2002).
Early stage KS lesions, particularly
those that fit into the original description
of patch and plaque types, rather than
nodular or invasive, tend to have many
fewer spindle and LANA-1-positive cells
and include apoptotic cells (Sturzl et al.,
1999). Most studies of clonality in KS
lesions have concluded that they are
either mixtures of oligoclonal cells or at
best only partially monoclonal, suggest-
ing that whereas some early develop-
ment may involve spread of infection to
new cells, the later nodular and invasive
stages probably involve cladal expansion
of proliferating populations that are now
virtually totally infected and lack an apo-
ptotic subset.
The two great puzzles of KSHV
oncogenesis are, firstly, considering that
KSHV clearly has the potential for caus-
ing neoplastic lesions and all KS lesions
have KSHV in them, why is KS so rare in
the absence of HIV? And secondly, how
can one rationalize why virtually all of the
unexpectedly large number of KSHV
genes that have been shown to have
some form of in vitro transforming or
potentially oncogenic properties fall into
the lytic cycle class rather than being
latent state genes?
In this issue of Cancer Cell,
Montaner and colleagues (2003) make
the best case yet that, despite being a
classic lytic cycle gene product, the viral-
ly encoded G protein-coupled receptor
(vGPCR or ORF74) gene is indeed the
predominant oncogene of KSHV. Most
investigators have agreed that in isola-
tion, the vGPCR protein, as a “captured”
relative of the cellular IL8 (α-chemokine)
receptor, has all of the right characteris-
tics, including constitutive (or ligand-
independent) MAPK signaling and
pro-angiogenic properties to explain the
vascular appearance of KS lesions. As
the laboratories of Mesri and Cesarman
have elegantly demonstrated, stable
ectopically expressed vGPCR induces
focus formation in NIH-3T3 cells, and
these cells in turn produce angiogenic
lesions resembling KS in nude mice.
Serine kinase-mediated intracellular sig-
naling by the vGPCR produces upregu-
lated PI3K/AKT and MAPK/ERK
pathways leading to increased AP1
activity and secreted VEGF production
and, in EC, to upregulation of the VEGF
receptor KDR (FLT-2) (Bais et al., 1998;
Cannon et al., 2003).
In the other well-studied γ her-
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A new mouse model reported in this issue of Cancer Cell implies that VEGF/KDR-mediated paracrine effects induced by the
lytic cycle vGPCR signaling protein encoded by human Kaposi’s sarcoma-associated herpesvirus (KSHV or HHV8) may be
involved in promoting the proliferation of the KSHV latently infected spindle endothelial cells of Kaposi’s sarcoma.
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pesvirus models for oncogenesis, only
latency genes are known to be essential
as contributors to immortalization of B
cells or T cells and for oncogenicity (e.g.,
LMP1 and EBNA2 in Epstein-Barr virus
or STP in Herpesvirus saimiri). In con-
trast, KSHV encodes at least five lytic
cycle proteins that either behave as
oncogenes in focus formation assays
(K1, vIRF1, vGPCR) or at least have
growth-promoting antiapoptotic or angio-
genic properties (vIL6, vMIP). Because
most PELs, MCD, and some KS sam-
ples, as well as KSHV-infected cultured
DMVEC spindle cells, display a low level
of spontaneous lytic cycle gene expres-
sion (usually in about 1% of the cells),
many authors have speculated that lytic
cycle gene expression may contribute to
the KS phenotype possibly via paracrine
effects. Normally we think of the lytic
cycle in herpesviruses as a process that
leads to rapid cell death. However, the
pattern of lytic cycle expression in both
PELs and DMVEC instead suggests a
hierarchy of abortive lytic progression in
which some cells express only one lytic
gene (vIL6) or just the earliest set of lytic
genes, including the immediate early
transcriptional regulators and one or
more viral β-chemokines (vMIP). Even
fewer cells also express the core DNA
replication proteins and the late early
vGPCR, and often there are very few or
no cells at all that express the true late
gpK8.1 protein (Chiou et al., 2002; Ciufo
et al., 2001). Therefore, some of these
abortive lytic stages may still be compat-
ible with cell survival or at least delayed
cell death. With regard to the vGPCR
gene, both the viral mRNA and its isolat-
ed upstream promotor display typical
PAA-insensitive early lytic cycle proper-
ties in both PELs and DMVEC, and are
not expressed significantly in the vast
majority of otherwise latently infected
cells. This applies also to vGPCR mRNA
and protein expression detected by in
situ hybridization or immunohistochem-
istry in KS lesion samples. However, a
small fraction of cells in some KS sam-
ples (particularly nodular cases) do
reveal typical lytic cycle levels of vGPCR
mRNA and protein expression (Chiou et
al., 2002; Kirshner et al., 1999).
Montaner et al. (2003) have asked
whether in vivo retrovirus-mediated
infection leading to specific expression of
vGPCR, vCYC-D, vFLIP, vIRF1, or
vBCL2 genes can produce KS-like
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Figure 1. Contributions of both latent and lytic viral proteins to KS pathogenesis
A: Schematic diagram illustrating the current model supported by Montaner et al. (2003) for conversion of endothelial cells (yellow cytoplasm) to
elongated spindle cells (LANA-positive nuclei in red) by KSHV latent infection, and the subsequent proliferative neoplasia of Kaposi’s sarcoma dri-
ven by paracrine effects from sporadic lytic cycle induction of vGPCR protein expression (black cytoplasm). 
B: Histological image of a human nodular KS biopsy tissue with large numbers of spindle cells (paraffin section, hematoxylin stain). 
C: Double label immunohistochemistry of a human nodular KS biopsy specimen showing both latent state infected LANA-positive spindle cells
(brown nuclear spots) and an occasional cell (arrowed) expressing the lytic cycle vGPCR protein (red cytoplasm) (from Chiou et al., 2002).
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lesions in mice. They found that this was
indeed the case, but only for vGPCR and
not for the other genes in isolation. The
authors chose an apparently very suc-
cessful and elegant approach for target-
ed expression in vascular EC using a
transgenic mouse expressing an avian
retrovirus receptor under the control of
an EC-specific enhancer domain.
Control infections with ALV-GFP showed
expression only in CD31-positive vascu-
lar EC, and the use of ALV expressing
wild-type vGPCR but not mutant vGPCR
yielded fast growing nodular KS-like vas-
cular lesions at high efficiency. Note that,
unlike human KS lesions, these mouse
tumors do not contain or express any
KSHV latency genes, but curiously just
like human KS, PEL, and infected
DMVEC, vGPCR expression occurred in
just a small fraction of the spindle-like
tumor cells. A similar fraction of tumor
cells (presumably the same cells) also
expressed VEGF and KDR. Most inter-
estingly, when infected EC expressing
either GFP or vCyc-D/vFLIP were coin-
jected together with vGPCR-expressing
cells, the former also contributed cooper-
atively to the mass of the tumor, although
they did not proliferate in the absence of
vGPCR. Furthermore, tumors that
included cells expressing the latency
genes (but not those including cells
expressing GFP) grew faster than those
with vGPCR only. Evidently, the pres-
ence of vGPCR-positive cells produced
paracrine or bystander effects that pro-
moted the propagation and survival of
the cells expressing latency genes,
which must already have exhibited some
extra level of growth dysregulation over
the GFP-only infected cells.
The strange pattern of vGPCR
expression in just a small percentage of
the mouse tumor cells is unexplained,
but is remarkably similar to the situation
in human KS, and even to that in another
about to be published study in which
transgenic mice receiving a vGPCR
gene under the control of the SV40-
enhancer again produced KS-like skin
EC lesions with confirmed vGPCR
expression in just a small fraction of the
tumor spindle cells (M. Reitz, personal
communication). Whether or not the
occasional cells that express vGPCR
survive long-term, these results create
an attractive scenario in which KS devel-
opment involves initial latent infection of
normal vascular EC, which converts
them into spindle cells, followed by a pro-
liferative phase requiring expression of
the early lytic cycle vGPCR protein in at
least a few spindle cells, with subse-
quent activation of a VEGF/KDR
autocrine loop plus apparent paracrine
effects on adjacent spindle cells that are
only latently infected (Figure 1).
This experimental model offers the
possibility of additional exciting develop-
ments in the future such as asking
whether including LANA-1 or vMIP or
even HIV TAT in vGPCR-driven tumors
contributes to tumor progression.
Although, in contrast to its cellular
counterparts such as CCR1, vGPCR evi-
dently has acquired the novel ability to
signal in a ligand-independent manner,
this signaling can still be up or down-
regulated by certain α-chemokine lig-
ands such as GROα and IP10,
respectively (Gershengorn et al., 1998).
If indeed the growth of the mouse KS-like
tumors can be manipulated positively or
negatively by GROα or IP10, this could
provide further strong support for a key
role of vGPCR signaling in KS
pathogenesis.
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